CombiMatrix is a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, pediatric developmental disorders and preimplantation genetic screening (PGS). As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix offers chromosomal microarray analysis, standard and customized FISH, and high resolution karyotyping to help clinicians better care for their patients. 
Type
Public
HQ
Irvine, US
Founded
1995
Size (employees)
55 (est)
CombiMatrix was founded in 1995 and is headquartered in Irvine, US
Report incorrect company information

Key People/Management at CombiMatrix

Scott Burell

Scott Burell

CFO
Judd Jessup

Judd Jessup

Chairman
Scott Gottlieb

Scott Gottlieb

Member of the Board of Directors
Karine Hovanes

Karine Hovanes

VP of Scientific Advancement & Laboratory Director
Robert E. Hoffman

Robert E. Hoffman

Member of the Board of Directors

CombiMatrix Office Locations

CombiMatrix has an office in Irvine
Irvine, US (HQ)
100 300 Goddard
Irvine, US
150 310 Goddard
Show all (2)
Report incorrect company information

CombiMatrix Financials and Metrics

CombiMatrix Financials

CombiMatrix's revenue was reported to be $12.87 m in FY, 2016 which is a 27.6% increase from the previous period.
USD

Revenue (Q3, 2017)

4 m

Gross profit (Q3, 2017)

2.4 m

Gross profit margin (Q3, 2017), %

59.8%

Net income (Q3, 2017)

(610 k)

EBIT (Q3, 2017)

(614 k)

Market capitalization (13-Nov-2017)

18.9 m

Cash (30-Sep-2017)

2.4 m
CombiMatrix's current market capitalization is $18.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

6.4 m8 m10.1 m12.9 m

Revenue growth, %

26%25%28%

Cost of goods sold

3.5 m4.4 m5.4 m5.8 m

Gross profit

2.8 m3.6 m4.6 m7.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.5 m1.8 m1.9 m2.1 m2.3 m2.5 m2.5 m3 m3.1 m3.2 m3.8 m4.2 m4 m

Cost of goods sold

845 k998 k1.1 m1.1 m1.2 m1.4 m1.4 m1.4 m1.4 m1.5 m1.5 m1.6 m1.6 m

Gross profit

658 k824 k888 k933 k1.1 m1.2 m1.1 m1.6 m1.7 m1.8 m2.3 m2.6 m2.4 m

Gross profit Margin, %

44%45%46%45%47%45%45%52%54%55%60%62%60%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.3 m1 m653 k2.7 m

Current Assets

16 m7.9 m7.2 m7.9 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

3.1 m1.5 m5.6 m4.7 m4.3 m3.2 m3 m2.4 m

Accounts Receivable

(1.3 m)

Current Assets

10.2 m8.6 m10.4 m9 m8.2 m7.4 m7.6 m7.2 m

PP&E

774 k746 k743 k717 k651 k587 k523 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.9 m)(8.7 m)(6.6 m)(4.1 m)

Depreciation and Amortization

698 k317 k297 k258 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(1.5 m)(2 m)(4.6 m)(7.1 m)(1.8 m)(3.4 m)(5.1 m)(1.5 m)(2.7 m)(3.6 m)(518 k)(888 k)(610 k)

Depreciation and Amortization

590 k71 k149 k235 k90 k168 k227 k64 k130 k195 k57 k122 k

Accounts Payable

884 k

Cash From Operating Activities

(4.1 m)(1.6 m)(4 m)(6.6 m)(1.2 m)(2.6 m)(4.2 m)(1.7 m)(2.5 m)(3.4 m)(495 k)(607 k)
USDY, 2017

Revenue/Employee

72.9 k

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information